Biknu (Carmustine) 100mg BSM US
Article:
B-16
Indications
- BiKNU is indicated as a palliative treatment alone or in approved combination therapy regimens with other approved chemotherapeutic agents for the following conditions:
- Malignant brain tumors: glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma and metastatic brain tumors.
- Multiple myeloma (in combination with prednisolone).
- Lymphogranulomatosis (as second-line therapy in combination with other approved drugs in patients with relapses during primary therapy or when it is ineffective).
- Non-Hodgkin's lymphoma (as second-line therapy in combination with other approved drugs in patients with disease recurrence during primary therapy or when it is ineffective).
- Malignant melanoma.
- 19ct
-
Commercial name:Biknu
-
Сhemical name:Carmustine
-
Dosage:100 mg
-
Release form:Ampoule
No reviews yet